ストックスクリーナーアプリを入手
0.311
2.54%
0.0077
アフターアワーズ：
.32
0.009
+2.89%
前日終値:
$0.3033
開ける：
$0.31
24時間の取引高:
252.89K
Relative Volume:
0.65
時価総額：
$20.44M
収益：
$1.22M
当期純損益:
$-14.15M
株価収益率:
-1.1962
EPS:
-0.26
ネットキャッシュフロー:
$-6.55M
1週間 パフォーマンス:
-2.75%
1か月 パフォーマンス:
-9.86%
6か月 パフォーマンス:
-19.43%
1年 パフォーマンス:
+5.46%
1日の値動き範囲:
$0.306
$0.3162
1週間の範囲:
$0.3006
$0.3281
52週間の値動き範囲:
$0.27
$0.9099
IGC Pharma Inc Stock (IGC) Company Profile
IGC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.311 | 20.44M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
IGC Pharma Inc (IGC) 最新ニュース
Market Recap: IGC Pharma Inc (IGC)’s Positive Momentum, Closing at 0.32 - The Dwinnex
Page 3 | IGC PHARMA INC Trade Ideas — TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease - Joplin Globe
Revolutionary Voice AI Could Detect Alzheimer's Before Symptoms ShowIGC's Breakthrough - StockTitan
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - ACCESS Newswire
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor - Markets Insider
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - AccessWire
Geode Capital Management LLC Has $240,000 Stock Holdings in IGC Pharma, Inc. (NYSEMKT:IGC) - Defense World
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - Big News Network
IGC Pharma to Unveil Alzheimer's Pipeline and AI Drug Discovery Updates at Investor Chat - StockTitan
Amazon To Sell Ad Tools To Third Parties - Baystreet.ca
IGC Gains on Word of Alzheimer’s Treatment - Baystreet.ca
IGC Pharma's CALMA Trial Triples Alzheimer's Patient Recruitment with AI-Powered Strategy - StockTitan
IGC Pharma to Present at BIO Partnering @ JPM 2025 Healthcare Conference - StockTitan
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock - MSN
Ascendiant Capital Markets Forecasts Strong Price Appreciation for IGC Pharma (NYSEMKT:IGC) Stock - Defense World
IGC Pharma expands clinical research program for IGC-AD1 - Nasdaq
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology - AccessWire
IGC Pharma's Alzheimer's Drug Shows 50% Memory Improvement in Early Studies - StockTitan
IGC.WS (India Globalization Capital) EV-to-FCF : 0.00 (As of Nov. 30, 2024) - GuruFocus.com
Otsuka Corp (OSUKF) QuotePress Release - The Globe and Mail
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial - Inkl
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment - BioSpace
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of He - GuruFocus.com
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasin - GuruFocus.com
IGC (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
IGC Pharma Reports 42% Revenue Growth, Advances Multiple Alzheimer's Drug Candidates - StockTitan
IGC Pharma CEO Reveals AI-Driven Strategy in Alzheimer's and Weight Loss Drug Development | IGC Stock News - StockTitan
IGC Pharma (STU:IGS1) Asset Turnover : 0.03 (As of Jun. 2024) - GuruFocus.com
MD’s IGC Pharma enrolls patients in Phase 2 trial for Alzheimer’s dementia drug - Maryland Daily Record
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - AccessWire
IGC Pharma Inc (IGC) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):